Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.
Tirzepatide
Also known as: Mounjaro, Zepbound
Tirzepatide is a dual GLP-1/GIP receptor agonist approved for type 2 diabetes (Mounjaro) and obesity (Zepbound). It has demonstrated unprecedented weight loss efficacy in clinical trials, with participants losing up to 20-25% of body weight. It represents the cutting edge of pharmaceutical weight management.
Risk Level
Medium RiskDifficulty
Beginner| CAS Number | 2023788-19-2 |
| Molecular Formula | C225H348N48O68 |
| Class | Peptide |
| Category | Fat Loss Agents |
Mechanism of Action
Tirzepatide activates both GLP-1 and GIP receptors simultaneously. GLP-1 activation slows gastric emptying, reduces appetite, and improves insulin sensitivity. GIP activation enhances the incretin effect and may independently promote fat oxidation and energy expenditure. The dual mechanism provides superior weight loss and glycemic control compared to GLP-1 agonists alone.
Dosing Research
Starting dose: 2.5 mg subcutaneous injection once weekly for 4 weeks. Titrated up by 2.5 mg every 4 weeks to a target of 10-15 mg weekly. Inject in abdomen, thigh, or upper arm. Rotate injection sites. Can be taken with or without food.
Side Effects & Risks
Nausea (most common, especially during titration), vomiting, diarrhea, constipation, decreased appetite, injection site reactions. Rare: pancreatitis, gallbladder disease, thyroid C-cell tumors (preclinical). Contraindicated with personal/family history of medullary thyroid carcinoma or MEN2. Muscle loss may occur without resistance training.
Research Studies
Related compounds
Semaglutide
PeptideSemaglutide is a GLP-1 receptor agonist approved for type 2 diabetes (Ozempic) and chronic weight management (Wegovy). Clinical trials demonstrated average weight loss of 15-17% of body weight. It has become one of the most widely discussed medications in modern weight management.
Liraglutide
PeptideLiraglutide is a GLP-1 receptor agonist approved for type 2 diabetes (Victoza, 1.8 mg) and obesity (Saxenda, 3.0 mg). It was the first GLP-1 agonist approved specifically for weight management. While effective, it has been largely superseded by semaglutide and tirzepatide in terms of weight loss efficacy.
T4 (Levothyroxine)
HormoneT4 (levothyroxine) is the primary thyroid prohormone produced by the thyroid gland. It is converted to the active T3 by deiodinase enzymes in peripheral tissues. It is the most commonly prescribed thyroid medication and provides a more stable, physiological approach to thyroid supplementation compared to T3.
T3 (Liothyronine)
HormoneT3 (triiodothyronine) is the active thyroid hormone that regulates basal metabolic rate. Liothyronine (Cytomel) is the synthetic form used medically for hypothyroidism. In performance settings, it is used to elevate metabolic rate and accelerate fat loss, often during cutting phases.
Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.